| 557 | For the treatment of initial episodes of Clostridium difficile infection; mild cases, if no response or intolerance to an adequate trial of oral metronidazole*:
*As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018.
Notes:
- Metronidazole 500mg orally three times daily for 10-14 days can be used in patients with mild diarrhea.
- Discontinue antibiotics for other indications if possible.
- Higher doses of vancomycin have not been shown to be beneficial.
- There is no evidence to support combination therapy with metronidazole or fidaxomicin.
Maximum funded dose: Vancomycin 125mg four times daily, up to 14 days
Maximum funded quantity: 56 capsules |
| | LU Authorization Period: 14 days |
| 558 | For the treatment of initial episodes of Clostridium difficile infection; moderate or severe, uncomplicated cases*:
*As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018.
Notes:
- Metronidazole 500mg orally three times daily for 10-14 days can be used in patients with mild diarrhea.
- For mild to moderate cases, treatment should only be continued beyond 7 days if diarrhea persists, up to a maximum of 14 days.
- Severe, uncomplicated cases should be treated for 10-14 days. There is no evidence to support treatment durations beyond 14 days.
- Higher doses of vancomycin have not been shown to be beneficial.
- There is no evidence to support combination therapy with metronidazole or fidaxomicin.
Maximum funded dose: Vancomycin 125mg four times daily, up to 14 days
Maximum funded quantity: 56 capsules |
| | LU Authorization Period: 14 days |
| 559 | For the treatment of recurrent Clostridium difficile infection (CDI), first recurrence, mild to moderate* or severe, uncomplicated* cases:
*As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018.
Notes:
- Recurrent CDI is defined as the reoccurrence of CDI within 8 weeks following the onset of a previous episode which resolved with treatment.
- Treatment should only be continued for 14 days.
- Higher doses or longer treatment duration with vancomycin have not been shown to be beneficial.
- There is no evidence to support combination therapy with metronidazole or fidaxomicin.
Maximum funded dose: Vancomycin 125mg four times daily, up to 14 days
Maximum funded quantity: 56 capsules |
| | LU Authorization Period: 14 days |
| 560 | For the treatment of recurrent Clostridium difficile infection (CDI), second or subsequent recurrences, mild to moderate* or severe, uncomplicated* cases:
*As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018.
Notes:
- Recurrent CDI is defined as the reoccurrence of CDI within 8 weeks following the onset of a previous episode which resolved with treatment.
- There is no evidence to support combination therapy with metronidazole or fidaxomicin.
Funded dose: Vancomycin 125mg four times daily for 10-14 days, followed by vancomycin taper.
Maximum funded quantity: 114 capsules |
| | LU Authorization Period: 13 Weeks |
